NCT06556732View on ClinicalTrials.gov

Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patients With Structural Heart Disease

PHASE1RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

August 10, 2024

Primary Completion Date

August 13, 2024

Study Completion Date

August 31, 2024

Conditions

Atrial Fibrillation

Interventions

DRUG

Eplereone

Group A (study group): 50 patients received eplerenon 25 mg daily plus amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin.

Trial Locations (1)

71526

RECRUITING

Assiut University Heart Hospital, Asyut

All Listed Sponsors

lead

Assiut University

OTHER